CANNABIS CULTURE – The cannabis industry in Brazil took a giant leap forward on April 7th when the country’s health regulatory agency (Agência Nacional de Vigilância Sanitária: ANVISA) gave a Good Manufacturing Practices – Pharma Grade (GMP) to the Brazilian branch of the multinational Ease Labs pharmaceutical group.
Ease Labs becomes the first cannabis company allowed to locally produce CBD products in the major South American market, as the certificate allows Ease Labs to develop, manufacture, store, import and export cannabis-based products in Brazil, making it a pioneer in this sector.
About Ease Labs
Ease Labs products are currently made in the United States and Europe, and they are subsequently distributed to its Brazilian clients by Ease Labs International, a Uruguayan branch of the group. Because Ease Labs’ products are made abroad the products come at a higher cost to patients.
In an interview with the author, Ease Labs CEO Gustavo de Lima Palhares explained that ANVISA’s authorization to produce cannabis products in Brazil is a victory for the entire Brazilian cannabis market, adding that easier, more affordable access for patients will happen sooner rather than later.